Glycine

Glycine

SCHEMBL421053

NCC(=O)O.NCC(=O)O.[Se]

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA1 P23415 1/20 0.91
SLC6A9 P48067 1/20 0.91
OR51E2 Q9H255 1/20 0.91
GABRR1 P24046 4/20 0.50
LMNA P02545 5/20 0.44
TSHR P16473 4/20 0.44
THRB P10828 3/20 0.44
BLM P54132 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GABRR3 A8MPY1 1/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
HDAC3 O15379 1/20 0.44
GABBR2 O75899 1/20 0.44
CYP1A2 P05177 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL1446288 1.00
Glycine SCHEMBL2116443 0.95
Glycine SCHEMBL391786 0.95 GLRA1 (1.00) GLRA1SLC6A9OR51E2GABRR1LMNA
Glycine SCHEMBL13169653 0.95
Glycine SCHEMBL6163 0.95
Glycine SCHEMBL93765 0.95 GLRA1 (1.00) GLRA1SLC6A9OR51E2GABRR1LMNA
Glycine SCHEMBL6675874 0.95 GLRA1 (1.00) GLRA1SLC6A9OR51E2GABRR1LMNA
Glycine SCHEMBL3640989 0.95 GLRA1 (1.00) GLRA1SLC6A9OR51E2GABRR1LMNA
Glycine SCHEMBL391027 0.95 GLRA1 (1.00) GLRA1SLC6A9OR51E2GABRR1LMNA
Glycine SCHEMBL30070584 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121574081-A Preparation method of soluble selenium glycine 郑州瑞普生物工程有限公司 2026-02-27 CN claimed
WO-2026044269-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ALZHEIMER'S DISEASE AND OTHER SAFWAT SHERIF (US) 2026-02-26 WO claimed
US-20240390415-A1 MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITS FP NUTRACEUTICALS LLC (US) 2024-11-28 US claimed
CN-118902017-A Mineral-enriched sausage and preparation method thereof 新疆迎安农牧科技有限公司 2024-11-08 CN claimed
CN-116986953-B Soil fertility-improving conditioner and preparation method thereof 史丹利化肥扶余有限公司 2024-04-16 CN claimed
CN-116986953-A Soil fertility-improving conditioner and preparation method thereof 史丹利化肥扶余有限公司 2023-11-03 CN claimed
CN-116549462-A Composition for improving sleep quality and application thereof 湖南微木生物科技有限公司 2023-08-08 CN claimed
US-20220118006-A1 MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITS HANCOCK WHITNEY BANK 2022-04-21 US claimed
US-11229667-B2 Magnesium/lithium preparations for neuroprotection and neurotrophic benefits FP NUTRACEUTICALS, LLC (US) 2022-01-25 US claimed
CN-113243397-A Preparation and application of special nutrition regulator for gramineous forage grass 中科韶华(四川)牧业研究院有限公司 2021-08-13 CN claimed
CN-112657270-A Nano water-soluble quantitative slow-release selenium-rich filter element for enhancing immunity and preventing cancers and diseases 硒收力(杭州)科技有限公司 2021-04-16 CN claimed
CN-106798158-B Chinese herbal medicine additive compound premix for laying hens and preparation method thereof 河南科技学院 2021-01-22 CN claimed
US-10039765-B1 Vitamin supplement compositions with enhanced bioavailability TOOTHMAN MICHELLE ANN (US) 2018-08-07 US claimed
US-20150132443-A1 PURIFICATION PROGRAM J/J Health Solutions, LLC 2015-05-14 US claimed
CN-121574081-A Preparation method of soluble selenium glycine 郑州瑞普生物工程有限公司 2026-02-27 CN disclosed
WO-2026044269-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ALZHEIMER'S DISEASE AND OTHER SAFWAT SHERIF (US) 2026-02-26 WO disclosed
US-20250090455-A1 SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS FP NUTRACEUTICALS, LLC (US) 2025-03-20 US disclosed
EP-0514451-B1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS LIFESCIENCE CORP (US) 1997-01-15 EP disclosed
EP-0514451-A1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. UNIV TEXAS (US) 1992-11-25 EP disclosed
WO-1991011117-A2 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10039765-B1 Vitamin supplement compositions with enhanced bioavailability SLC19A1, SLC19A2, VKORC1L1 GLRA1 3543/4885SLC6A9 322/4885OR51E2 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.